Alexion Pharmaceuticals - PharmaKB

Company Reports

Company Reports

Disease Reports

Disease Reports

Company ReportsAlexion Pharmaceuticals

Alexion Pharmaceuticals(ALXN)

Alexion Pharmaceuticals is an American pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases. It became an independent subsidiary of AstraZeneca in 2021.

Download report

Favorite

Financial

Marketed Drugs

Clinical Trials

Financial

Stock price

*Currency in USD

Company Revenue

Quarterly

Quarterly

Annual

Annual

Projections

*Quarterly sales USD (in millions)

Plot placeholder

Mock data
Subscribe for the real data

Revenue by Drug

Marketed Drugs

Therapeutic Areas:

All

Classification:

All

Include Generics:

Trade Name	Drug Name	Approved	Patent Expires	Indication
Kanuma	Sebelipase alfa	2015-12-08		Inborn errors lipid metabolism
Soliris	Eculizumab	2007-03-16		Paroxysmal hemoglobinuria , Myasthenia gravis , Atypical hemolytic uremic syndrome
Strensiq	Asfotase alfa	2015-10-23		Hypophosphatasia
Ultomiris	Ravulizumab	2018-12-21		Paroxysmal hemoglobinuria, Atypical hemolytic uremic syndrome

Clinical Trials

Therapeutic Areas:

All

Classification:

All

Approval:

All

Status:

All

Phases:

All

Drug Name

Phase 1

Phase 2

Phase 3

Phase 4

Indication

hypophosphatasia

Sebelipase alfa

,

cholesterol ester storage disease

,

,

failure to thrive

glomerulonephritis

,

membranoproliferative glomerulonephritis

,

,

end stage liver disease

,

,

kidney transplantation

,

kidney diseases

,

,

anti-neutrophil cytoplasmic antibody-associated vasculitis

,

,

,

,

complement activation

,

psychology rejection

,

chronic renal insufficiency

,

hemolytic anemia autoimmune

,

,

macular degeneration

,

geographic atrophy

,

,

,

,

hemolytic-uremic syndrome

,

atypical hemolytic uremic syndrome

,

myasthenia gravis

,

neuromyelitis optica

,

muscle weakness

,

delayed graft function

,

guillain-barre syndrome

,

left ventricular dysfunction

,

ventricular dysfunction

,

escherichia coli infections

,

shiga-toxigenic escherichia coli

,

phenylketonurias

,

paroxysmal hemoglobinuria

,

,

,

respiratory distress syndrome

,

,

acute lung injury

,

hypophosphatasia

,

severe acute respiratory syndrome

,

viral pneumonia

,

,

newborn respiratory distress syndrome

,

,

disease progression

healthy volunteers/patients

,

hepatic insufficiency

,

renal insufficiency

,

glomerulonephritis

,

membranoproliferative glomerulonephritis

,

macular degeneration

,

geographic atrophy

,

,

paroxysmal hemoglobinuria

,

,

Mycophenolate sodium

multiple sclerosis

,

,

kidney transplantation

,

systemic scleroderma

,

,

diffuse scleroderma

,

renal insufficiency

,

carotid artery diseases

,

atherosclerosis

,

kidney diseases

,

healthy volunteers/patients

,

,

drug interactions

pharmacokinetics

Mycophenolic acid

multiple sclerosis

,

,

kidney transplantation

,

systemic scleroderma

,

,

diffuse scleroderma

,

renal insufficiency

,

carotid artery diseases

,

atherosclerosis

,

kidney diseases

,

b-cell chronic lymphocytic leukemia

,

,

t-cell lymphoma

,

hodgkin disease

,

follicular lymphoma

,

b-cell lymphoma

,

t-cell lymphoma cutaneous

,

bronchiolitis obliterans syndrome

,

non-hodgkin lymphoma

coronary artery disease

,

cardiopulmonary bypass

,

coronary artery bypass

Choline alfoscerate

healthy volunteers/patients

,

autoimmune diseases

,

1

2

3

4

5

>

© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use